Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Exclusion Criteria

• •Prior administration of weekly paclitaxel.
• •Tumours of malignant mixed mesodermal (MMMT) or mucinous subtypes, or non-epithelial ovarian cancers (e.g. Brenner tumours, Sex-cord tumours).
• •Unresolved bowel obstruction.
• •Chemotherapy within the preceding 3 weeks.
• •Radiotherapy within the preceding 3 weeks.
• •Treatment with any investigational agent within the preceding 4 weeks or within 5 half-lives of the investigational agent, whichever is longer.
• •Known leptomeningeal involvement or intracranial disease.
• •Evidence of interstitial lung disease (bilateral, diffuse, parenchymal lung disease).
• •Resting ECG with measurable QTc interval of \>480 msec at 2 or more time points within a 24 hour period.
• •Pregnant or lactating females.
• •Fertile women of childbearing potential not willing to use highly effective contraception for the duration of trial treatment and for at least 6 months after the last administration of saracatinib +/- paclitaxel.
• •Inability or unwillingness to give informed consent.
• •Ongoing active infection or a documented history of HIV infection, Hepatitis B or C.
• •Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease.
• •Concurrent autoimmune disorder, e.g. systemic lupus or any demyelinating disease.
• •Use of immunosuppressive therapy or corticosteroids taken within the 4 weeks prior to study entry and during the treatment period.